全球的糖尿病治療市場： 2005 - 2015 年

Abstract

This report details the worldwide incidence and prevalence by country/region of Type 1 and Type 2 diabetes and details the current and projected market for diagnostic and therapeutic products in the management of diabetes, including anti-diabetic drugs, alternative insulin types, blood glucose monitoring (including continuous monitoring devices), insulin pumps, and other established and emerging products in diabetes management. The report provides an emphasis of detail on the status of development of novel products including noninvasive monitoring, oral/inhaled/other insulin delivery. The report details the clinical and technology developments underlying this huge and evolving worldwide market, with data on products in development and on the market; market size and forecast; competitor market shares; competitor profiles; and market opportunity. Separate size, growth and competitor share data are presented for the U.S., individual western European countries (Belgium, Denmark, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, United Kingdom), and Japan. The report profiles active companies including detailed profile information on major competitors, brief profiles of companies with less sizeable current or potential positions in the market, and appropriate additional profiles of companies with novel or advanced research activities in the market.

The report establishes the current worldwide market size for major technology segments as a baseline for and projecting growth in the market over a ten-year forecast. The report also assesses and projects the composition of the market as technologies gain or lose relative market performance over this period.

Table of Contents

EXECUTIVE SUMMARY

• Some Diabetes Basics
• A Large and Growing Market
• A Many-Sided Market
• Pharmaceuticals for Diabetes
• Insulin
• Oral Anti-diabetic Drugs
• The Pharmaceutical Diabetes Market
• Insulin Administration Devices
• Medical Devices for Diabetes
• Total Diabetes Market
• Regional Segmentation
• Market Growth
• The Diabetes Industry
• Pharmaceutical Companies
• Medical Device Companies

SECTION 1: ABOUT DIABETES

• 1.1 What is Diabetes?
• 1.2 Blood Sugar Regulation
  • 1.2.1 Insulin
• 1.3 Main Types of Diabetes
  • 1.3.1 Type 1 Diabetes
  • 1.3.2 Type 2 Diabetes
  • 1.3.3 Gestational Diabetes
  • 1.3.4 Obesity-Related type 2 Diabetes in Children.
  • 1.3.5 Mature-onset Diabetes of the Young (MODY)
  • 1.3.6 Other Diabetic States
• 1.4 Diagnosis
  • 1.4.1 Glucose Tests
  • 1.4.2 Official Criteria
  • 1.4.3 Differential Diagnosis
    • 1.4.3.1 Type 1 Diabetes
    • 1.4.3.2 Type 2 Diabetes
• 1.5 Current Treatment
  • 1.5.1 Type 1 Diabetes
  • 1.5.2 Type 2 Diabetes
  • 1.5.3 Diet
• 1.6 Future Treatment Approaches
• 1.7 Treatment Monitoring
  • 1.7.1 Blood Sugar Control
  • 1.7.2 The Diabetes Control and Complications Trial
  • 1.7.3 Glycated haemoglobin (HbA1c)
  • 1.7.4 Fructosamine
• 1.8 Incidence and Prevalence of Diabetes
  • 1.8.1 Worldwide
    • 1.8.1.1 Type 1
    • 1.8.1.2 Type 2
  • 1.8.2 USA
    • 1.8.2.1 Type 1
    • 1.8.2.2 Type 2
  • 1.8.3 Japan
    • 1.8.3.1 Type 1
    • 1.8.3.2 Type 2
  • 1.8.4 Europe
    • 1.8.4.1 Type 1
    • 1.8.4.2 Type 2
• 1.9 Diabetic Complications
  • 1.9.1 Retinopathy
  • 1.9.2 Neuropathy
  • 1.9.3 Nephropathy
• 1.10 Metabolic Syndrome

SECTION 2: PRODUCTS USED IN DIAGNOSIS AND MONITORING

• 2.1 Blood Glucose Monitoring Devices: Suppliers and Products
  • 2.1.1 Lancets
  • 2.1.2 Blood Sampling Devices
    • 2.1.2.1 Bayer Diagnostics
    • 2.1.2.2 Becton Dickinson
    • 2.1.2.3 Cell Robotics
    • 2.1.2.4 LifeScan
    • 2.1.2.5 Roche Diagnostics
  • 2.1.3 Blood Glucose Monitors
    • 2.1.3.1 77 Elektronica Kft
    • 2.1.3.2 Abbott Laboratories
    • 2.1.3.3 Acon Laboratories Inc.
    • 2.1.3.4 Apex Biotechnology Corp.
    • 2.1.3.5 Bayer Corporation
    • 2.1.3.6 Becton Dickinson & Co
    • 2.1.3.7 Belbiosens
    • 2.1.3.8 Cygnus Inc -- Animas Corp
    • 2.1.3.9 Diagnostic Devices Inc.
    • 2.1.3.10 Eumed Biotechnology Co. Ltd.
    • 2.1.3.11 HMD Bio Medical
    • 2.1.3.12 Glucoplus Inc
    • 2.1.3.13 HemoCue AB
    • 2.1.3.14 Home Diagnostics Inc
    • 2.1.3.15 Hypoguard
    • 2.1.3.16 LifeScan Inc
    • 2.1.3.17 Medtronic MiniMed
    • 2.1.3.18 Polymer Technology Systems Inc.
    • 2.1.3.19 QuestStar Medical Inc
    • 2.1.3.20 Roche
    • 2.1.3.21 TaiDoc Technology Corporation
    • 2.1.3.22 US Diagnostics Inc.
  • 2.1.4 New Developments in Glucose Testing
• 2.2 'Artificial Pancreas'
  • 2.2.1 Medtronic
  • 2.2.2 Roche
  • 2.2.3 Abbott
  • 2.2.4 Novo Nordisk/LifeScan
• 2.3 Other Testing Approaches
  • 2.3.1 Haemoglobin A1c
    • 2.3.1.1 Hemoglobin A1c Meters
    • 2.3.1.2 Hemoglobin A1c Kits
• 2.4 Software Programs for Diabetes Monitoring.
  • 2.4.1 Web Software
  • 2.4.2 Commercial Software

SECTION 3: PRODUCTS USED IN TREATMENT

• 3.1 Insulin
  • 3.1.1 History
    • 3.1.1.1 Bovine and Porcine Insulin
    • 3.1.1.2 Humanized Insulin
  • 3.1.2 Companies Supplying Insulin
    • 3.1.2.1 Eli Lilly
    • 3.1.2.2 Aventis
    • 3.1.2.3 Novo Nordisk
    • 3.1.2.4 Some Other Suppliers
  • 3.1.3 Insulin Delivery
    • 3.1.3.1 Syringes
  • 3.1.4 Insulin Syringe Manufacturers
    • 3.1.4.1 Pens
    • 3.1.4.2 Manufacturers of Insulin Pens
    • 3.1.4.3 Injectors
    • 3.1.4.4 Injector Manufacturers
  • 3.1.5 Inhaled insulin
  • 3.1.6 Pfizer/Sanofi-Aventis/Nektar Therapeutics
    • 3.1.6.1 Lilly/Alkermes
    • 3.1.6.2 Novo Nordisk/Aradigm
    • 3.1.6.3 MannKind
  • 3.1.7 Insulin Pumps
    • 3.1.7.1 What is an Insulin Pump?
    • 3.1.7.2 The Infusion Set
    • 3.1.7.3 Candidates for Pump Therapy
  • 3.1.8 Companies Supplying Insulin Pumps
    • 3.1.8.1 Animas Corporation
    • 3.1.8.2 DANA Diabecare
    • 3.1.8.3 Medtronic MiniMed
    • 3.1.8.4 Nipro Diabetes Systems
    • 3.1.8.5 Roche Disetronic
    • 3.1.8.6 Smiths Medical
• 3.2 Oral Hypoglycaemic Drugs
  • 3.2.1 Sulfonylureas
  • 3.2.2 Biguanides
  • 3.2.3 Alpha-Glucosidase Inhibitor
  • 3.2.4 Thiazolidinediones
  • 3.2.5 Prandial Glucose Regulators
  • 3.2.6 Incretin Mimetics
  • 3.2.7 Amylin Mimetic
  • 3.2.8 New Products Now in R&D

SECTION 4: NOVEL APPROACHES TO DIABETES MANAGEMENT

• 4.1 Pancreas Transplants
• 4.2 Islet Cell Transplants
  • 4.2.1 Edmonton Protocol
  • 4.2.2 Improving ICT
  • 4.2.3 Living-Donor Islet Cell Transplant
• 4.3 Stem Cell Developments
  • 4.3.1 ADA Endorsement
  • 4.3.2 Stem Cell Research at EASD 2005
  • 4.3.2.1 Adult Stem Cells
• 4.4 Antibody Treatment
• 4.5 Vaccines
  • 4.5.1 Diamyd Medical
  • 4.5.2 DeveloGen
• 4.6 Genetic Approaches
  • 4.6.1 Genetic Testing
  • 4.6.2 Small-interfering RNA (SiRNA)
• 4.7 Novel Drugs
  • 4.7.1 DDP-IV Inhibitors
  • 4.7.2 Other Drugs
  • 4.7.3 All-in-one Treatment for Type 2 Diabetes?
• 4.8 Continuous Glucose Monitoring
  • 4.8.1 Electroenzymatic Sensor
  • 4.8.2 Optical Glucose Sensor
  • 4.8.3 Sensor Based on Carbon Nanotubes

SECTION 5: THE DIABETES MARKET

• 5.1 Global Market
  • 5.1.1 Size
  • 5.1.2 Growth
  • 5.1.3 Regional Segmentation
• 5.2 Market Analysis by Product Category
  • 5.2.1 Monitoring Products
    • 5.2.1.1 Major Suppliers
  • 5.2.2 Insulins and Insulin Delivery Devices
    • 5.2.2.1 Major Suppliers
  • 5.2.3 Oral Antidiabetic Drugs
    • 5.2.3.1 Major Suppliers
• 5.3 Trends
• 5.4 Main National Markets
  • 5.4.1 Belgium
  • 5.4.2 Denmark
  • 5.4.3 France
  • 5.4.4 Germany
  • 5.4.5 Italy
  • 5.4.6 Japan
  • 5.4.7 Netherlands
  • 5.4.8 Norway
  • 5.4.9 Spain
  • 5.4.10 Sweden
  • 5.4.11 United Kingdom
• 6.1.5.4.12 USA

SECTION 6: COMPANY PROFILES

• 6.1 Leading Companies
  • 6.1.1 Abbott Laboratories
    • 6.1.1.1 Overview
    • 6.1.1.2 Diabetes Products
    • 6.1.1.3 Pipeline
    • 6.1.1.4 Financials
  • 6.1.2 Bayer
    • 6.1.2.1 Overview
    • 6.1.2.2 Diabetes Products
      • 6.1.2.2.1 Ascensia Blood Glucose Monitoring
    • 6.1.2.3 Financials
  • 6.1.3 Becton Dickinson
    • 6.1.3.1 Overview
    • 6.1.3.2 Diabetes Products
      • 6.1.3.2.1 Insulin Injection Devices
      • 6.1.3.2.2 Glucose Monitoring Products
      • 6.1.3.3 Financials
  • 6.1.4 Bristol-Myers Squibb
    • 6.1.4.1 Overview
      • 6.1.4.1.1 Problems with Generics
    • 6.1.4.2 Diabetes Products
    • 6.1.4.3 Financials
  • 6.1.5 Eli Lilly
    • 6.1.5.1 Overview
    • 6.1.5.2 Diabetes Products
    • 6.1.5.3 Financials
    • 6.1.5.4 Pipeline
  • 6.1.6 Glaxo SmithKline
    • 6.1.6.1 Overview
    • 6.1.6.2 Diabetes products
    • 6.1.6.3 Financials
    • 6.1.6.4 Pipeline
  • 6.1.7 Johnson & Johnson
    • 6.1.7.1 Overview
    • 6.1.7.2 Diabetes Products
    • 6.1.7.3 Financials
  • 6.1.8 Medtronic
    • 6.1.8.1 Overview
    • 6.1.8.2 Diabetes Products
      • 6.1.8.2.1 Paradigm 512/712 insulin pump
      • 6.1.8.2.2 Paradigm 515/715 insulin pump
      • 6.1.8.2.3 CGMS System Gold
    • 6.1.8.3 Financials
    • 6.1.8.4 Pipeline
  • 6.1.9 Merck KgaA
    • 6.1.9.1 Overview
    • 6.1.9.2 Diabetes Product
    • 6.1.9.3 Financials
  • 6.1.10 Novartis
    • 6.1.10.1 Overview
    • 6.1.10.2 Diabetes Product
    • 6.1.10.3 Financials
    • 6.1.10.4 Pipeline
  • 6.1.11 Novo Nordisk
    • 6.1.11.1 Overview
    • 6.1.11.2 Diabetes Products
      • 6.1.11.2.1 Pharmaceuticals
    • 6.1.11.3 Financials
    • 6.1.11.4 Pipeline
  • 6.1.12 Pfizer
    • 6.1.12.1 Overview
    • 6.1.12.2 Diabetes Products
    • 6.1.12.3 Financials
    • 6.1.12.4 Pipeline
  • 6.1.13 Roche
    • 6.1.13.1 Overview
    • 6.1.13.2 Diabetes Products
      • 6.1.13.2.1 Accutrend GC/GCT
    • 6.1.13.3 Financials
    • 6.1.13.4 Pipeline
  • 6.1.14 Sanofi-Aventis
    • 6.1.14.1 Overview
    • 6.1.14.2 Diabetes Products
    • 6.1.14.3 Financials
    • 6.1.14.4 Pipeline
  • 6.1.15 Takeda
    • 6.1.15.1 Overview
    • 6.1.15.2 Diabetes Products
    • 6.1.15.3 Financials
    • 6.1.15.4 Pipeline
      • 6.1.15.4.1 TAK-559
      • 6.1.15.4.2 TAK-654
• 6.2 Other Companies
  • 6.2.1 77 Elektronica
  • 6.2.2 Acon Laboratories
  • 6.2.3 Activa
  • 6.2.4 AdipoGenix
  • 6.2.5 AgaMatrix
  • 6.2.6 AiMedics Pty Ltd
  • 6.2.7 Alkermes Inc.
  • 6.2.8 Amylin
  • 6.2.9 Animas Corp.
  • 6.2.10 Antares Pharma
  • 6.2.11 Apex Biotechnology Ltd
  • 6.2.12 Aradigm
  • 6.2.13 Arena Pharmaceuticals
  • 6.2.14 B Braun
  • 6.2.15 Belbiosens
  • 6.2.16 Benitec Limited
  • 6.2.17 Biocon
  • 6.2.18 Bioject Medical Technologies Inc.
  • 6.2.19 BioSafe Medical Technologies Inc
  • 6.2.20 Biovitrum
  • 6.2.21 Cell Robotics International, Inc
  • 6.2.22 ChemGenex Pharmaceuticals Ltd
  • 6.2.23 Dana Diabecare USA
  • 6.2.24 Devgen NV
  • 6.2.25 Dexcom Inc
  • 6.2.26 Diabetes Technologies Inc.
  • 6.2.27 Diagnostic Devices Inc.
  • 6.2.28 Diosynth
  • 6.2.29 EnGene
  • 6.2.30 Equidyne Corporation
  • 6.2.31 Eumed Biotechnology Co. Inc
  • 6.2.32 FivePrime Therapeutics
  • 6.2.33 FlexSite Diagnostics
  • 6.2.34 Fluent Biomedical Inc
  • 6.2.35 GlucoLight Corporation
  • 6.2.36 Glucon Medical Ltd
  • 6.2.37 Glucoplus Inc
  • 6.2.38 GluMetrics LLC
  • 6.2.39 Hemocue AB
  • 6.2.40 Hitachi Ltd
  • 6.2.41 HMD Biomedical
  • 6.2.42 Home Diagnostics Inc
  • 6.2.43 HypoGuard
  • 6.2.44 Infratec Inc
  • 6.2.45 InLight Solutions Inc
  • 6.2.46 Integrity Applications Ltd
  • 6.2.47 Kumetrix Inc
  • 6.2.48 Laboratorios Beta
  • 6.2.49 LifeTrac Systems Inc
  • 6.2.50 Ligand Pharmaceuticals Inc
  • 6.2.51 MannKind
  • 6.2.52 Menarini
  • 6.2.53 Metabolex
  • 6.2.54 Metrika Inc.
  • 6.2.55 Nektar Therapeutics
  • 6.2.56 Nipro Diabetes Systems Inc
  • 6.2.57 Owen Mumford
  • 6.2.58 Palco Laboratories
  • 6.2.59 Pelikan Technologies
  • 6.2.60 Pindi Products
  • 6.2.61 Polymer Technology Systems Inc
  • 6.2.62 Provalis plc
  • 6.2.63 QuestStar Medical Inc
  • 6.2.64 Quotient Diagnostics Ltd
  • 6.2.65 Rosch AG Medizintechnik
  • 6.2.66 Sanwa Kagaku Kenkyusho Co. Ltd.
  • 6.2.67 SenSys Medical
  • 6.2.68 Laboratoires Servier
  • 6.2.69 Sirna Therapeutics
  • 6.2.70 Smiths Medical
  • 6.2.71 Sontra Medical Corporation
  • 6.2.72 SpectRx Inc
  • 6.2.73 TaiDoc Technology Corporation
  • 6.2.74 Terumo Medical Corporation
  • 6.2.75 Theratechnologies Inc.
  • 6.2.76 TolerRx Inc.
  • 6.2.77 US Diagnostics Inc
  • 6.2.78 Vaxine Pty Ltd.
  • 6.2.79 VeraLight Inc.
  • 6.2.80 Vivo Medical Inc.
  • 6.2.81 Wockhardt Ltd

List of Exhibits

• Exhibit ES-1: Total Diabetes Market, 2004
• Exhibit ES-2: Regional Segmentation of Diabetes Market
• Exhibit 1.1: Threshold Glucose Levels Indicative of Diabetes/Hyperglycemia (mmol/L)
• Exhibit 1-2: Main Brands and Types of Insulin
• Exhibit 1-3: Oral Diabetes Treatments
• Exhibit 1-4: Prevalence of Diabetes by Region (Age 20-79 Years)
• Exhibit 1-5: Differences in the Prevalence of Type 2 Diabetes Among Selected Ethnic Groups, 2003
• Exhibit 1-6: Prevalence of Diabetes in USA, 2003
• Exhibit 1-7: Incidence of Type 1 Diabetes in Western European countries (Cases per 100,000 Child Population, per Annum)
• Exhibit 1-8: Type 1 Diabetes Incidence Growth Rates in Selected European Countries
• Exhibit 1-8: Estimated Prevalence of Type 2 Diabetes in Western European Countries
• Exhibit 2-1: International Suppliers of Blood Lancets
• Exhibit 2-2: Blood Glucose Meters
• Exhibit 2-3: Research Projects in Glucose Monitoring
• Exhibit 2-4: Commercial Software Programs for Windows and Macintosh
• Exhibit 3-1: Major Brands of Insulin
• Exhibit 3-2: Manufacturers of Insulin Pens
• Exhibit 3-3: Manufacturers of Insulin Pups
• Exhibit 3-4: Sulfonylureas
• Exhibit 3-5: Oral Hypoglycemics
• Exhibit 5-1: Prevalence of Diabetes Mellitus, by Selected Country, 2003 and 2025 (Percent of Population Age 20-79)
• Exhibit 5-2: Global Diabetes Market 2004
• Exhibit 5-3: Relative Market Size of Major Regional Diabetes Markets; USA, Western Europe and Japan
• Exhibit 5-4: Glucose Monitors: Leading Companies 2004
• Exhibit 5-5: Market for Insulin and Other Diabetes Medications, Belgium, 2003-2015
• Exhibit 5-6: Market for Glucose Meters, Belgium, 2003-2015
• Exhibit 5-7: Market for Insulin Pumps, Belgium, 2003-2015
• Exhibit 5-8: Market for Insulin and Other Diabetes Medications, Denmark, 2003-2015
• Exhibit 5-9: Market for Glucose Meters, Denmark, 2003-2015
• Exhibit 5-10: Market for Insulin and Other Diabetes Medications, France, 2003-2015
• Exhibit 5-11: Market for Glucose Meters, France, 2003-2015
• Exhibit 5-12: Market for Insulin Pumps, France, 2003-2015
• Exhibit 5-13: Market for Insulin and Other Diabetes Medications, Germany, 2003-2015
• Exhibit 5-14: Market for Glucose Meters, Germany, 2003-2015
• Exhibit 5-15: Market for Insulin Pumps, Germany, 2003-2015
• Exhibit 5-16: Market for Insulin and Other Diabetes Medications, Italy, 2003-2015
• Exhibit 5-17: Market for Glucose Meters, Italy, 2003-2015
• Exhibit 5-18: Market for Insulin Pumps, Italy, 2003-2015
• Exhibit 5-19: Market for Insulin and Other Diabetes Medications, Japan, 2003-2015
• Exhibit 5-20: Market for Glucose Meters, Japan, 2003-2015
• Exhibit 5-21: Market for Insulin Pumps, Japan, 2003-2015
• Exhibit 5-22: Market for Insulin and Other Diabetes Medications, Netherlands, 2003-2015
• Exhibit 5-23: Market for Glucose Meters, Netherlands, 2003-2015
• Exhibit 5-24: Market for Insulin Pumps, Netherlands, 2003-2015
• Exhibit 5-25: Market for Insulin and Other Diabetes Medications, Norway, 2003-2015
• Exhibit 5-26: Market for Glucose Meters, Norway, 2003-2015
• Exhibit 5-27: Market for Insulin Pumps, Norway, 2003-2015
• Exhibit 5-28: Market for Insulin and Other Diabetes Medications, Spain, 2003-2015
• Exhibit 5-29: Market for Glucose Meters, Spain, 2003-2015
• Exhibit 5-30: Market for Insulin Pumps, Spain, 2003-2015
• Exhibit 5-31: Market for Insulin and Other Diabetes Medications, Sweden, 2003-2015
• Exhibit 5-32: Market for Glucose Meters, Sweden, 2003-2015
• Exhibit 5-33: Market for Insulin Pumps, Sweden, 2003-2015
• Exhibit 5-34: Market for Insulin and Other Diabetes Medications, United Kingdom, 2003-2015
• Exhibit 5-35: Market for Glucose Meters, United Kingdom, 2003-2015
• Exhibit 5-36: Market for Insulin Pumps, United Kingdom, 2003-2015
• Exhibit 5-37: Market for Insulin and Other Diabetes Medications, United States, 2003-2015
• Exhibit 5-38: Market for Glucose Meters, United States, 2003-2015
• Exhibit 5-39: Market for Insulin Pumps, United States, 2003-2015
• Exhibit 6-1: Abbott Laboratories Financial Data, 2004
• Exhibit 6-2: Bayer Group Financials, 2004
• Exhibit 6-3: Becton Dickinson Financials, 2004
• Exhibit 6-4: Bristol-Myers Squibb Financials, 2004
• Exhibit 6-5: Eli Lilly Financials, 2004
• Exhibit 6-6: Glaxo SmithKline Financials, 2004
• Exhibit 6-7: Glaxo SmithKline Diabetes Products in Research Pipeline
• Exhibit 6-8: J&J Medical Devices and Diagnostics Financials, 2004
• Exhibit 6-9: Medtronic Financials, 2004
• Exhibit 6-10: Merck KGaA Financials, 2004
• Exhibit 6-11: Novartis Financials, 2004
• Exhibit 6-12: Novo Nordisk Financials, 2004
• Exhibit 6-13: Pfizer leading products
• Exhibit 6-14: Pfizer Financials, 2004
• Exhibit 6-15: Roche Financials, 2004
• Exhibit 6-16: Sanofi Aventis, Leading Products 2004
• Exhibit 6-17: Sanofi-Aventis Financials, 2004
• Exhibit 6-18: Takeda Leading Products
• Exhibit 6-19: Takeda Financials, 2005